Detected HER2-positive CTCs in patients with early-stage breast cancer [145,146] and patients that had HER2-positive CTCs before neoadjuvant therapy were associated with shortened disease-free survival and OS [35]. This evidence concerns the gene ERBB2 and breast carcinoma.